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Interferon-g inhibits experimental renal fibrosis
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Interferon-g inhibits experimental renal fibrosis. of an identified cell type or types by therapeutic interven-
Background. Recent evidence has implicated myofibroblasts tion aimed at retarding the progression of chronic renal
as a cell type responsible for the laying down of extracellular failure (CRF). Myofibroblasts are activated fibroblastsmatrix components during fibrosis in a number of organs. In
expressing cytoskeletal proteins such as a-smooth musclethis study, we examined the capacity of interferon-g (IFN-g)
actin (a-SMA), which attribute to these cells contractileto inhibit the activation of fibroblasts to the myofibroblastic
phenotype and hence reduce the extent of renal scarring in the and migratory properties similar to those of smooth mus-
rat subtotal nephrectomy (SNx) model using a novel method of cle cells [1]. These cell types are involved in normal wound
intrarenal delivery. healing as they participate in tissue retraction and repair
Methods. Rats were divided into four groups: sham, SNx
[2]. Recently, attention has focused on the contribution(group 1), SNx 1 drug vehicle (group 2) and SNx 1 IFN-g
of myofibroblasts to tissue scarring and fibrosis, particu-(400 units/day; group 3) for 30 days. Rats were sacrificed on
days 15, 30, 45, and 90 following SNx. larly that of the kidney [3, 4]. Work from our laboratory
Results. Clinical data showed a marked reduction in protein- has defined the course of myofibroblastic cells in the
uria in the group treated with IFN-g (161 vs. 280 mg/24 hr by glomeruli and interstitium of rats with immune- and non-
day 45, P , 0.01) and a preservation of the creatinine clearance immune-mediated nephropathies [5, 6]. In the subtotal(1.16 vs. 0.84 ml/min by day 45, P , 0.05) when compared to
(5/6) nephrectomy (SNx) rat model of experimental re-the SNx or SNx 1 vehicle groups throughout the time course.
nal scarring, we noted the colocalization of interstitialImmunohistochemical staining for a-smooth muscle actin
(a-SMA) revealed a reduction in myofibroblastic cell types myofibroblasts with monocytes and fibrogenic growth
(6.5 6 3.1% glomerular a-SMA in group 3 compared with 14.8 6 factors [6]. The postulated role of myofibroblasts in the
4.2% glomerular a-SMA in group 2, P , 0.05, 3.8 6 1.4% pathogenesis of renal fibrosis is based on their potentialtubulointerstitial a-SMA in group 3 compared with 8.8 6 2.0%
to synthesize components of the extracellular matrix [3].tubulointerstitial a-SMA in group 2 on day 45, P , 0.05).
In identifying factors that stimulate the activation ofThere was also a reduction in immunostaining for collagens
III and IV in the IFN-g–treated group. Scoring for both glomer- myofibroblasts, cytokines and particularly transforming
ulosclerosis and tubulointerstitial fibrosis in the IFN-g group growth factor-b1 (TGF-b1) have been strongly impli-
(group 3) was lower than the other two operated groups. cated [2, 7]. By contrast, interferon-g (IFN-g) is a potentConclusions. We conclude that IFN-g, administered at a dose
inhibitor of a-SMA expression in fibroblasts [2, 8].of 400 units/day, has a strong inhibitory effect on myofibroblasts
Because of their availability as recombinant proteins,and that as a possible result of this action, renal fibrosis is
reduced and renal function is preserved in the rat SNx model. multiple biological activities have been ascribed to the
The IFN-g renoprotective effect lasted only for the extent of IFNs that are not restricted to the immune system. IFN-g,
its administration and subsided when discontinued. a product of activated T cells and natural killer (NK)
cells, exerts prominent antiproliferative and cytostatic
effects. It down-regulates collagen synthesis in human
The complete understanding of the contribution of normal dermal fibroblasts [9], inhibits smooth muscle
various cell types in the process of experimental renal cell proliferation [10], and inhibits collagen synthesis in
scarring remains a subject of speculation. Thus far, this vivo in the mouse [11]. At least part of the antifibrogenic
lack of knowledge has hindered the effective targeting response to IFN-g is thought to be through regulation
of collagen gene expression by transcriptional and post-
transcriptional mechanisms [12]. However, its inhibitoryKey words: tubulointerstitial fibrosis, myofibroblasts, interferon-g, re-
nal scarring. effects on myofibroblasts must also contribute to the
overall antifibrotic effect of this cytokine.Received for publication December 23, 1998
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pump proves prohibitively expensive when applied to a kidney tissue were then anchored using a small spot of
veterinary adhesive (Vetbondt, 3 M Company, Minne-large study. Furthermore, we also felt that the limited
efficacy of systemic administration of IFN-g may have apolis, MN, USA). The cannula was then channeled
through the abdominal muscle layer, which was sutured,been due to the potential of this cytokine to up-regulate
the immune and inflammatory responses as well as the and connected to a primed 2 ML2 Alzett osmotic mini-
pump (Charles River Ltd., Kent, UK) situated in a subcu-expression of major histocompatibility complex (MHC)
and cell adhesion molecules. We therefore decided to taneous pocket. The osmotic minipump contained either
the drug or its vehicle. The skin covering the minipumpuse the technique of intrarenal administration. This is a
modified technique similar to those described by Mattson was then sutured. The administration of the drug or
vehicle to groups 2 and 3 was for a period of 30 dayset al [14] and Matejka and Jennische [15] whereby the
drug is fed directly into the renal parenchyma by means (from SNx to day 30), after which time the pump was
exhausted though remained in situ. Animals and theirof a fenestrated cannula attached to a subcutaneously
implanted minipump. This method allows much smaller controls in all three groups were killed in groups of six
on days 15, 30, 45, and 90 after surgery. Kidneys weredoses of the drug to be used and hence studies to be
carried out for longer periods. It also allows high concen- collected with the cannulae in situ and fixed overnight
in 10% neutral-buffered formalin (Sigma Biochemicals,trations of the drug to be delivered directly to the kidney
without interfering and confounding systemic influences. Dorset, UK). Following fixation, renal tissue was embed-
ded in paraffin, and 5 mm sections were cut for bothThe aim of this study was to investigate the effects of
intrarenally administered IFN-g on myofibroblasts in the histological and immunohistochemical analysis.
SNx rat, as measured by a-SMA accumulation, and to
Delivery cannulaeinvestigate whether this ultimately affected renal fibrosis
and function in these animals. Uniform lengths of sterile cannula tubing [outer diam-
eter (OD) 1 mm, interior diameter (ID) 0.6 mm; Portex
Ltd., Kent, UK] were secured to a sterile glass tile. With
METHODS
the aid of a dissecting microscope, five equidistant punc-
Surgical procedure ture holes were made in the tubing using the pointed
ends of a pair of sterile curved watchmakers forceps, theExperiments were performed on 250 to 300 g male
Wistar rats (Sheffield University strain). Animals were distance from the first hole to the last hole being 8 mm
in each case. The open (renal) end of each cannula wasallowed normal rat chow (LabSure, Cambridge, UK) and
tap water ad libitum before and throughout the experi- heat sealed and then trimmed and smoothed. This
method of cannula production was found to be extremelymental procedure. All of the experimental procedures
were carried out according to the rules and regulations reproducible in terms of hole size and placing. Com-
pleted sterile cannulae were filled, attached to the regula-laid down by the Home Office (Animals; Scientific Proce-
dures Act 1986, UK). Rats were divided into the follow- tor of an osmotic minipump, and primed (Fig. 1).
ing three experimental groups: group 1, SNx rats (N 5
Interferon-g24); group 2, SNx with intrarenal cannula delivering drug
vehicle [phosphate-buffered saline (PBS)/0.1% bovine Each rat in group 3 received 400 units/day of recombi-
nant rat IFN-g (Genzyme Diagnostics, Kent, UK) dilutedserum albumin (BSA), N 5 24]; and group 3, SNx with
intrarenal cannula delivering IFN-g (400 m/day, N 5 24). in PBS containing 0.1% BSA. This dose was calculated
on the basis that the subcutaneous dose required for aThree additional groups of rats (N 5 24) were included
as sham-operated controls. This involved deep anesthe- full animal was 20,000 units/day [13]. Because the drug
is delivered directly into the renal tissue without systemicsia followed by exposure and gentle manipulation of the
kidneys. influence, the amount of drug required is considerably
less. Working from successful doses in cell culture [10,For all surgical procedures, rats were anesthetized with
halothane. SNx was undertaken as a single-step proce- 16] and orders of magnitude of other drugs administered
by this method in this laboratory (abstract; Haylor et al,dure as described previously [6]. Briefly, this involved
right nephrectomy followed by partial left nephrectomy J Am Soc Nephrol 8:637, 1997) and others [14, 15], a
working dose of 400 units/day was reached.(ligation and resection of the upper and lower poles). In
rats undergoing implantation of a renal cannula, this The administration of the IFN-g into the renal tissue
by the fenestrated cannula unit was first verified in twowas performed at the same time as SNx; following the
removal of the upper and lower poles of the kidney, ways: first, three subtotally nephrectomized rats by load-
ing the minipumps with 125I-labeled IFN-g (Amersham,the fenestrated end of the cannula was passed into and
through the renal cortex longitudinally until it reap- Little Chalfont, Buckinghamshire, UK) at the same con-
centration and delivery rate as the experimental animals.peared at the opposite surface. The upper and lower
parts of the cannula immediately entering/leaving the These animals were left until the delivery life of the
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was determined for each group prior to sacrifice at each
time point.
Blood pressure was taken prior to sacrifice by the tail-
cuff method using a Model 229 (IITC Inc. Life Science
Instruments, Woodland Hills, CA, USA) blood pressure-
monitoring machine.
Estimation of renal scarring
Renal scarring was assessed by one of the authors
(S.D.O.) blinded to the experimental code following SNx
according to a 0 to 3 arbitrary scale as described pre-
viously [6]: score 5 0, normal glomerulus; score 5 1,
mild segmental glomerulosclerosis (GS) affecting up to
25% of the glomerular tuft; score 5 2, moderate GS
affecting between 25 and 50% of the glomerular tuft;
and score 5 3, severe GS affecting in excess of 50% of
the glomerular tuft.
A minimum of 30 glomeruli were scored, and the mean
was calculated and assigned to each experimental animal.
Damaged tubulointerstitium were also assessed along these
lines: score 5 0, normal tubulointerstitium; score 5 1,
mild tubular atrophy and interstitial edema or fibrosis
affecting up to 25% of an objective field at magnification
3200; score 5 2, moderate tubulointerstitial fibrosis
(TIF) affecting between 25 and 50% of a given field; and
score 5 3, severe TIF exceeding 50% of a given field.
A minimum of 12 randomly selected, nonoverlapping
fields were evaluated, and the mean score was calculated.
Scarring estimations were made using sections stained
with hematoxylin and eosin under an Olympus BH-2
Fig. 1. Photographs showing (A) the drug delivery system of osmotic
light microscope with flat field objective. Data were col-minipump and fenestrated cannula and (B) close up of the cannula
showing fenestrations. lected for a minimum of 12 randomly selected cortical
fields for each section.
Immunohistochemical staining
Sections were dewaxed and hydrated in graded etha-pump had expired and were then killed. The blood, urine,
nol solutions. Sections were then treated with 0.1% H2O2and major organs were collected and counted for radio-
for 30 minutes to quench endogenous peroxidase activ-activity in a g counter. This ensured that the method
ity. Following rinsing, sections were then pretreated with
used did not result in peritoneal leakage or systemic
0.1% trypsin (Zymed, Cambridge, UK) for 10 minutes
delivery of the drug and that we had produced cannulae at 378C. Sections were incubated for 20 minutes in diluted
with patent fenestrations. Second, two groups of SNx normal blocking serum (1.5%; Vector Laboratories, Pe-
rats (N 5 4) had implanted cannulae connected to mini- terborough, UK) to suppress nonspecific binding of IgG.
pumps loaded with either rat recombinant IFN-g or its Sections were incubated at 48C overnight with the pri-
saline vehicle. Following one week of administration, mary antibody (a-SMA 1:200 provided by G. Gabbiani;
rats were sacrificed, and kidneys were fixed and sec- ED1 1:100 for monocytes/macrophages, Serotec, Oxford,
tioned. Sections were immunostained using an antirat UK; and collagens III 1:100 and IV 1:100, Europath,
recombinant IFN-g antibody (R&D Systems, Abingdon, Cornwall, UK) in a humidified chamber. Following rins-
UK) at a concentration of 1 mg/ml or a nonimmune ing steps, the sections were then incubated for 30 minutes
control IgG. with biotin-conjugated secondary antibody then 30 min-
utes with avidin biotin reagent (Vector). Color was de-
Evaluation of renal function veloped using a commercial AEC kit (Vector). Sections
The creatinine concentration in both serum and 24- were finally counterstained in hematoxylin and were
hour urine samples (standard autoanalyzer techniques), mounted. Controls included sections stained after the
omission of the primary antibody or stained with IgG atas well as urinary protein excretion (Biuret method),
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Table 1. Clinical parameters following sham operation (Sham)
or SNx (Groups 1–3)
Body Creatinine Urinary Blood
weight clearance protein pressure
g ml/min mg/24 hr mm Hg
Sham
Day 15 338.968.4 1.3260.13 41.667.7 13768.6
Day 30 347.1613.9 1.3060.09 47.263.8 135610.2
Day 45 354.5611.6 1.3860.18 48.569.4 14369.8
Day 90 356.0617.2 1.3360.15 52.8610.4 142611.4
Group 1
Day 15 340.569.4 0.8060.04 111612.3 13864.5
Day 30 351.4611.0 0.9160.05 244650.0 13063.0
Day 45 357.4616.4 0.8460.06 278653.0 13763.1
Day 90 353.7619.5 0.7360.14 421668.6 15263.5
Group 2
Day 15 344.2610 0.8360.04 100615.4 13863.0
Day 30 347.069.1 0.8860.07 261658.4 12765.0Fig. 2. Distribution of 125I-IFN-g following intrarenal administration
Day 45 359.7614.5 0.9660.07 295662.0 13463.9from a one-day Alzett osmotic minipump.
Day 90 360.4612 0.7260.24 439675.0 14962.8
Group 3
Day 15 338.7610.5 1.1860.08a 55.8610.9a 12465.0
Day 30 349.169.4 1.1860.07a 88.8612.9b 11168.0a
Day 45 358.0611.3 1.1660.08a 161.5669.2b 11162.8athe same protein concentration as experimental anti-
Day 90 356.5615.2 0.7160.16 240.8663.6b 11763.3abodies.
a P , 0.05, b P , 0.01 when compared to Group 2Sections were analyzed using a drawing tube and a 25-
point squared lattice relying on a standard morphometric
analysis based on point counting [6]. Data were collected
from a series of 12 nonoverlapping adjacent fields ex- In SNx rats given IFN-g, strong staining was localized
tending perpendicularly from the cortex to the medulla. to both the glomeruli and the tubulointerstitial areas.
The percentage points falling on stained structures (cell Generally, there appeared to be a much greater and
or interstitium) were estimated, and the percentage of widespread distribution of immunodetectable IFN-g in
glomeruli stained was calculated. this group of animals.
Statistical analysis General observations
Analysis of data from clinical, histological, and immu- Remnant kidney nephropathy followed the expected
nohistochemical studies were by one-way analysis of course, which included increasing proteinuria, systemic
variance using Excel software. Multiple regression analy- hypertension, and a progressive decline in renal function
sis (RGRESS) and testing of individual predictor sig- (Table 1).
nificance within any group of predictors were carried out
Functional parametersusing Minitab software. A P value of less than 0.05 was
considered significant. Creatinine clearance (CCr) values were significantly
decreased in groups 1 (SNx alone) and 2 (SNx plus vehi-
cle) when compared with group 3 (SNx plus IFN-g) fromRESULTS
day 15 onward (P , 0.05) and remained significantly
Distribution of interferon-g lower at the following two time points, days 30 and 45.
The amount of recovered labeled IFN-g taken from By day 90, the CCr in group 3 rats had declined, and there
the rats following sacrifice is illustrated in Figure 2. The was no significant difference between the three groups
total amount of recovered 125I-IFN-g was 79 6 6.3% of at this time point. CCr data are illustrated in Figure 4.
that administered in each minipump. Each minipump All rats in groups 1 and 2 were significantly more
was counted following sacrifice to ensure that the full proteinuric by day 15 (P , 0.05) when compared with
contents of the pump had been delivered. Of the recov- group 3 rats, and this remained the case throughout the
ered counts, over 70% were found in the urine of each time course. From day 30 onward, this increase became
animal, with remainder being in the kidney (15%) and more significant (P , 0.01), as illustrated in Figure 4.
the blood (3.5%). Only minimal counts were recovered Mean blood pressure measurements showed no sig-
from the liver, lung, and heart. Immunohistochemical nificant difference between the three groups on day 15,
staining for rat recombinant IFN-g following one week although by day 30 and onward, group 3 had significantly
of SNx is shown in Figure 3. In SNx rats given saline lower blood pressure values than the other two groups.
vehicle, only a weak staining could be seen in the glomer- Absolute values for all clinical parameters including
data for sham-operated animals are shown in Table 1.uli, with no staining present in the tubulointerstitial areas.
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Fig. 3. Immunolocalization of rat recombinant IFN-g throughout kidneys from (A) saline vehicle-treated SNx rats and (B) rat recombinant IFN-g–
treated SNx rats following one week of administration.
Fig. 6. Photomicrographs of representative fields of immunolocalization of a-smooth muscle actin in day 45 group 2 animals (A and B) and day
45 group 3 animals (C and D).
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Fig. 4. Histogram showing (A) creatinine clearance and (B) urinary protein in rats of groups 1 through 3 following SNx. *P , 0.05, **P , 0.01
with respect to group 2 (SNx plus vehicle). Symbols are: (h) sham operated; ( ) group 1; ( ) group 2; ( ) group 3.
Fig. 5. Histogram showing (A) glomerulosclerosis and (B) tubulointerstitial fibrosis in rats of groups 1 through 3 following SNx. *P , 0.05, **P ,
0.01 with respect to group 2 (SNx plus vehicle). Symbols are: (h) sham operated; ( ) group 1; ( ) group 2; ( ) group 3.
Renal scarring (P , 0.05). By day 90, although numerically lower, the
comparison between group 3 and groups 1 and 2 was noThe sham-operated control group showed no increase
longer significant (Fig. 5).in either glomerular or TIF throughout the duration of
the time course. There was a significant decrease in GS
Immunohistochemical staining for a-smoothin group 3 over the other two groups on days 15 and 30
muscle actin(P , 0.05), although by day 45, there was no difference
Staining for immunoreactive a-SMA was successful inbetween the groups, all having increased over the three-
all groups studied, with extensive staining of the vascularmonth period (Fig. 5). A similar pattern was evident for
media in sections from each group. Staining was detectedTIF, with a significant lowering of the score in group 3
as opposed to groups 1 and 2 on days 15 through 45 in the media of arteries and arterioles in normal (sham-
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Fig. 7. Histogram showing the changes in a-SMA staining in the three groups throughout the experimental time course. (A) in glomeruli and
(B) in tubulointerstitium. *P , 0.05; **P , 0.01 with respect to group 2 (SNx plus vehicle). Symbols are: (h) sham operated; ( ) group 1; ( )
group 2; ( ) group 3.
operated) kidneys. Figure 6 shows representative photo- jacent to the fenestrated portion of the cannula (Fig. 8).
We observed no discernible difference in ED-1 immuno-micrographs of sections from each group, and Figure 7
staining both generally and around the cannula betweenthe overall trends. In groups 1 and 2, a-SMA immuno-
group 2 (SNx 1 vehicle) and group 3 (SNx 1 IFN-g).stain increased steadily from day 30, with only vascular
staining visible on day 15. Staining occurred in both the
Immunohistochemical staining for collagens III and IVglomeruli, in a mesangial distribution and in interstitial
Staining for these two collagen types revealed a reduc-areas, particularly in the later stages of the time course,
tion in collagen deposition in group 3 rats when com-and was maximal on day 90. In group 3 rats, staining for
pared with groups 1 and 2 for both collagen types. In alla-SMA was minimal in regions excluding the vascular
groups, staining for collagen III was localized aroundmedia until its appearance on day 45, and this was in-
vessels and tubulointerstitial areas and was observablecreased by day 90. Groups 1 and 2 stains were not statisti-
from day 15, although group 3 rats, which had beencally different, whereas group 3 values were consistently
administered IFN-g, showed a significantly decreasedlower throughout the time course and significantly so at
collagen III score following point counting when com-day 45. In tubulointerstitial areas, a similar pattern of
pared with both groups 1 and 2 at the earlier time pointsstaining emerged, with group 3 rats exhibiting reduced
of days 30 and 45 (Figs. 9 and 10). Collagen IV was
a-SMA staining throughout the time course when com-
localized to the glomerular basement membrane and
pared with groups 1 and 2. By day 90, in all groups,
vascular walls with scant staining of tubulointerstitial
staining was strong and localized in both glomeruli and areas in group 3 rats. In the two SNx groups not receiving
tubulointerstitium. No significant difference could be IFN-g, groups 1 and 2, there was much more widespread
found between the groups at this time point. staining in the expanded interstitial matrix between days
30 to 90, although by day 90, staining for both collagen
Immunohistochemical staining for ED-1 types was comparable in all groups (Figs. 9 and 10).
Localization of monocytes/macrophages by ED-1 stain-
Correlation of a-smooth muscle actin staining withing was performed primarily to establish whether the
renal fibrosisact of cannulating the kidney stimulated recruitment of
inflammatory cells, particularly around the cannula when R2 values and significance (P) values on days 30, 45,
in situ. In all groups, staining at the earlier time points and 90 following SNx for group 2 (SNx 1 vehicle) and
of days 15 and 30 revealed only moderate macrophage/ group 3 (SNx 1 IFN-g) animals were calculated for
individual parameters. Glomerular a-SMA–positive cellmonocyte recruitment around the zone immediately ad-
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Fig. 8. Photomicrographs of representative fields of immunolocaliza- Fig. 9. Photomicrographs of representative fields of immunolocaliza-
tion of ED-1 in group 2 animals. tion of collagen III in group 3 animals (A), group 1 animals (B), group
2 animals (C and D) at day 45, and collagen IV in group 3 animals (E)
and group 1 (F) at day 30.
scoring demonstrated a positive correlation with both
GS and tubulointerstitial a-SMA–positive cell scoring
(P , 0.05) in group 2 rats on day 30, whereas this glomer- binant rat IFN-g on the expression of a-SMA and its
ular a-SMA–positive cell scoring was not significant in correlation with fibrosis in kidneys of rats submitted to
group 3-treated rats on day 30, although it did correlate extensive renal ablation through SNx. We feel that the
with tubulointerstitial a-SMA (P , 0.05). By day 45, implications of the results of this study are threefold.
both glomerular and tubulointerstitial a-SMA correlated First, we can conclude that the method of intrarenal drug
significantly with GS and TIF, respectively, in group 2 delivery is viable in this experimental setting. Second,
animals, whereas in group 3 animals, a significant correla- the act of cannulation does not appear to significantly
tion regarding a-SMA only existed between glomerular alter the functional, immunological, or biochemical pa-
and tubulointerstitial scoring of a-SMA and not with rameters of the “normal” remnant kidney in the rat.
scarring parameters (P , 0.05). By day 90, both groups Third, at the current dose of 400 units/day, IFN-g amelio-
2 and 3 showed a similar significance of correlations with
rates renal fibrosis, reduces myofibroblast activation, re-
regard to a-SMA staining scoring. Significantly, inhibi-
duces proteinuria, and preserves renal function for thetion of a-SMA scoring showed a stronger correlation to
duration of its administration.reduced scarring parameters than those of blood pres-
During wound healing and fibrotic diseases, fibroblas-sure throughout the time course.
tic cells undergo a characteristic phenotypic modulation
conferring on them several features of smooth muscle
DISCUSSION cells. The main features of these myofibroblasts are the
development of an extensive cytoplasmic microfilamentIn this study, we have observed a beneficial effect
during the period of intrarenal administration of recom- apparatus, biochemically characterized by the expression
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Fig. 9. (Continued).
of a-SMA. a-SMA and microfilaments disappear when a support the notion that this cytokine exerts an antifi-
brotic effect.wound heals [17], but persist during the fibrocontractive
changes observed in Dupuytren’s disease and hypertro- Interstitial staining of a-SMA–positive myofibroblasts
in our laboratory has previously been shown to havephic scarring [18]. The role of the myofibroblast in the
development of fibrocontractive diseases and renal fi- a distribution comparable to that of type IV collagen,
possibly derived from phenotypic changes within renalbrosis is well established [4, 19]. The mechanisms leading
to the development of cytoskeletal features similar to interstitial fibroblasts leading to their expression of
a-SMA and the acquisition of contractile properties [4].those of activated myfibroblasts including the factors that
can regulate, in vivo and in vitro, the appearance of A close association between the presence of interstitial
myofibroblasts and type IV collagen in biopsies froma-SMA remain to be elucidated. The most likely candi-
dates for such actions are the cytokines, which can be patients with interstitial fibrosis has been reported pre-
viously [3]. A similar association has also been observedlocally released by vascular cell types, inflammatory cells,
and fibroblastic cells themselves. The inhibition of in patients with liver cirrhosis where myofibroblasts and
type IV collagen are colocalized in fibrous septa [23].a-SMA expression by IFN-g has been documented be-
fore in both smooth muscle cells [20] and fibroblasts [8]. This study confirms previous observations relating to
changes in amounts of interstitial collagens followingWhen IFN-g is applied directly to Dupuytren’s nodules,
it produces an improvement in the hypertrophic scars in treatment with IFN-g [11, 12]. Whether the reduction in
the amounts of collagens observed in the IFN-g–treatedaddition to the reduction of the size of the lesion and
elicits the disappearance of a-SMA in myofibroblasts group in this experiment is directly or indirectly caused
by the modulation of myofibroblasts remains to be eluci-[21]. The accepted actions of IFN-g on collagen metabo-
lism [11, 12] and on fibroblast replication [22] further dated, although the decreased number of a-SMA–positive
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Fig. 10. Histogram showing the changes in collagen III (A) and collagen IV (B) staining in the three groups throughout the experimental time
course. *P , 0.05, **P , 0.01 with respect to group 2 (SNx plus vehicle). Symbols are: (h) sham operated; ( ) group 1; ( ) group 2; ( ) group 3.
cells would suggest an association. It is interesting to of IFN-g on blood pressure was observed (Table 1), a
significant inhibitory effect was still noted in group 3 ratsnote that in group 3 rats, although by 90 days most of
the parameters measured were now similar to group 2, on proteinuria, CCr, GS, TIF, and collagen IV expression.
At this first time point, the a-SMA expression score wasproteinuria was still significantly reduced. It may be that
following IFN-g administration proteinuria in this model reduced in both glomeruli and interstitium in group 3
rats as compared with group 2 rats. Finally, it was ob-lags behind other markers studied such as collagens and
a-SMA. It is certainly evident that urinary protein in served that some individual SNx rats treated with IFN-g
remained as hypertensive as untreated SNx rats whilegroup 3 was on the increase from day 45, and had the
study been extended would have been expected to reach still showing a reduction in fibrotic indices.
Of interest are the observations in our model of a lackvalues comparable to those of group 2 rats.
Without a functional in vivo concentration-response of macrophage/monocyte accumulation either to a large
extent around the implantation site of the cannula or incurve to IFN-g in this model, it is only possible to estab-
lish that the administered dose has been effective by the glomeruli. In a previous study in mesangial proliferative
nephritis, the authors observed no significant reductioninhibition of myofibroblast activation as seen in group 3.
A complete concentration-response curve in this model in the amounts of a-SMA expression despite inhibition
of mesangial cell proliferation following a subcutaneoususing this mode of delivery is still required for IFN-g,
as is a sufficient study of the possible protective effects administration of IFN-g [13]. This was attributed to the
ability of IFN-g to increase glomerular macrophages andof the lowering of blood pressure in our model by the
administration of IFN-g. Indeed, the effects of IFN-g on transforming growth factor-b expression, and the authors
drew attention to the potential discrepancies between inblood pressure cannot be completely dismissed, with the
possibility that the inhibition of myofibroblasts and fibrosis vitro and in vivo data in relationship to the antifibrotic
effects of IFN-g. We feel our method of administrationis a secondary event to the amelioration of hypertension
in group 3 rats. We feel that given the well-documented may more closely resemble those of in vitro experimenta-
tion whereby many of the systemic influences and metab-effects of IFN-g on myofibroblasts allied to the observa-
tions that correlations between the reduction in myofibro- olism of drug are bypassed. There were no significant
increases in ED-1 staining in group 3 (IFN-g) rats overblast number and the inhibition if fibrosis were stronger
than those for blood pressure, the direct action of IFN-g the other two control groups, although the time points
examined in this study were later than those reported inon these cell types is a more likely explanation for the
antifibrotic effects observed. To strengthen this point the anti–Thy-1 model [13], so any possible early increase
cannot be strictly excluded. Furthermore, the modelfurther, changes in fibrotic indices preceded changes in
blood pressure. At day 15, when no beneficial effect failed to show any unfavorable effects in vivo regarding
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renal morphology and function. Lupus mice treated with volved in tryptophan metabolism, and the inhibitory ef-
IFN-g systemically exhibit increased proteinuria [24], a fects of IFN-g on MMPs are thought to be due to the
parameter that in this study showed the most remarkable depletion of tryptophan [32]. Tryptophan is a precursor
reduction in terms of extent and duration. Increased for the synthesis of biologically important amines and
glomerular sclerosis was observed with IFN-g treatment at high concentrations directly stimulates MMP gene
in a murine model of IgA nephropathy [25], raising the expression [33].
possibility that the effects of IFN-g on disease processes One further factor that may warrant consideration is
or outcomes may be dependent on the type of disease the effect of IFN-g on T-cell activation in the kidney
studied and perhaps more importantly the extent of im- during intrarenal administration. Interstitial lymphocytes
munological contribution to a specific disease or the trigger a series of events leading to the synthesis of fibro-
route of administration. genic cytokines and stimulation of extracellular matrix
The apparent antifibrotic role of IFN-g must be bal- expression by resident cells. T-cell activation by IFN-g
anced against the findings of increased inflammation in could act to negate in some part the amelioration of
two transgenic mouse models in which this cytokine is renal function and pathology, and were this not the case,
overexpressed [26, 27]. In one animal, IFN-g was linked the net renoprotective effect could possibly be greater.
to the human insulin promoter, leading to high levels of These findings, coupled with the recent observations
expression in the pancreas. These animals exhibited a that in IFN-g gene knockout mice glomerular pathology
striking accumulation of mononuclear inflammatory cells, is accelerated and proteinuria increased in a nephritis
islet cell destruction, and diabetes mellitus. In the other (abstracts; Saleem et al, J Am Soc Nephrol 8:465A, 1997,
model, IFN-g was overexpressed in the liver by means Ring et al, J Am Soc Nephrol 9:467A, 1998), warrant
of a construct, including a liver-specific promoter. After further investigation of the potential protective and anti-
one year, these mice displayed bile duct proliferation, fibrotic effects of IFN-g in the kidney.
necrosis, and inflammation consistent with chronic hepa-
titis. Interestingly and in contrast to the inflammatory ACKNOWLEDGMENTS
disease in human liver, fibrosis was absent in these ani-
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thase (iNOS) [28]. Indeed, sequence analysis of the pro-
moter/enhancer region of the mouse iNOS gene revealed
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